ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Aldeyra securities may be entitled to compensation through a class action without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Aldeyra [2]. Group 2: Regulatory Issues and Stock Performance - On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, indicating a lack of substantial evidence for the drug's efficacy in treating dry eye disease [3]. - Following the FDA's announcement, Aldeyra's stock price dropped by $2.99 per share, a decline of 70.7%, closing at $1.24 per share on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized for its success in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].